Penumbra, Inc. Schedules Fourth Quarter and Full Year 2024 Earnings Release and Conference Call for February 18, 2025
Penumbra (NYSE: PEN) has scheduled its fourth quarter and full year 2024 earnings release and conference call for February 18, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Penumbra (NYSE: PEN) has scheduled its fourth quarter and full year 2024 earnings release and conference call for February 18, 2025. The company will issue a press release detailing financial results after market close, followed by a conference call at 4:30 PM Eastern Time.
Investors can access the conference call by dialing (888) 596-4144 with conference ID 5872954, or join via webcast through the 'Events and Presentations' section on Penumbra's website. The webcast recording will remain available for at least two weeks after the call.
Details
News Market Reaction – PEN
The recorded move for PEN in the trading session of this news was +2.85%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Webcast & Conference Call Information
The conference call can be accessed live over the phone by dialing (888) 596-4144 (conference id: 5872954), or the webcast can be accessed on the "Events and Presentations" section under the "Investors" tab of the company's website at www.penumbrainc.com. The webcast will be available on the company's website for at least two weeks following the completion of the call.
About Penumbra
Penumbra, Inc., the world's leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity. By pioneering these innovations, we support healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life. For more information, visit www.penumbrainc.com and connect on Instagram, LinkedIn and X.
Investor Relations
Penumbra, Inc.
investors@penumbrainc.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/penumbra-inc-schedules-fourth-quarter-and-full-year-2024-earnings-release-and-conference-call-for-february-18-2025-302356557.html
SOURCE Penumbra, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.